amgen weight loss news - Search News

Amgen Stock Dives

Barron's on MSN · 2d

Amgen Stock Dives After Weight-Loss Drug Data. Here’s What to Know.

Amgen stock was dropping sharply Tuesday after releasing what looked like positive data from a Phase 2 study for its experimental monthly weight-loss shot MariTide.Overweight or obese patients on MariTide lost 20% of their body weight on average,

Amgen's weight-loss drug fails to impress in study; shares plunge

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Newsweek on MSN · 11h

Amgen Obesity Drug More Effective Than Competitors

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

2d

Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

1d

Amgen price target lowered to $330 from $360 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results